Riku Lähteenmäki

Public biotechnology 2004—the numbers

Last year, public biotech companies made gains in revenues and profits, but with stock markets lackluster and regulatory issues looming, future growth remains uncertain.

Public biotech 2013[mdash]the numbers

2013 was truly a year to remember for the public biotech sector, with the largest wave of IPOs since the 2000–2001 bubble.

Public biotech 2009—the numbers

T whooshing sound at the end of 2009 was the biotech sector letting out its collective breath. The year began as a hard slog, so when it came to a close on an upward swing, the industry rightfully felt a measure of relief. That’s not to say there weren’t casualties: a distressingly large number of companies departed the scene last year. But it was not as bad as some pundits had estimated, and the industry proved itself to be strong and creative. It was helped by a recovering economy in the second half of the year. Overall, counting the vast financial potential of collaborations, the industry recorded one of its best years for fundraising. That has left the sector brightly looking ahead again—a far cry from how things appeared at the end of 2008.The public biotech sector sustained more losses in 2009, but the year ended on a positive note, and the industry has regained its footing.

Public biotech 2011—the numbers

The financial performance of the public biotech sector was remarkably buoyant last year, but a few worrying clouds hover on the horizon.

Public biotech 2010[mdash]the numbers

585 Brady Huggett is Business Editor and John Hodgson is Editor-at-Large at Nature Biotechnology. Riku Lähteenmäki is a freelance writer in Turku, Finland. increased 141% to 1,393 deals last year, which raised

Public biotech 2008—the numbers

284.6 billion (up 153%). Those figures were buoyed in particular by a record-breaking fourth quarter in 2010. All of this would lead one to suspect that the public biotech sector had a fine year; our data—and this article—will show it did.

Finnish biotechnology--built on solid foundations.

The sour global economy has left many small public firms gasping for air.

Public biotech in 2015 - the numbers.

Committed investment in research infrastructure has laid the foundations for a vibrant biotechnology community in Finland.

Public biotech 2007—the numbers

Last year witnessed the biotech sectors first retreat from a multi-year run of incredible performance on the public markets.

Public biotechnology 2002|[mdash]|the numbers

Record profits and financing in the public biotech sector may be unsustainable in the coming years as economies falter.